Refine by
Insulin Resistance Articles & Analysis: Older
10 news found
Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and environmental factors, characterized by increased plasma glucose levels, mainly due to insufficient insulin secretion or dysfunction in the body (insulin resistance). Diabetes can be categorized into three primary forms - type 1, ...
In turn, the insulin signaling pathway is a signal transduction that regulates glucose homeostasis by controlling glucose and lipid metabolism. When pancreatic beta cells release insulin in response to elevated nutrient levels, it binds to insulin receptors, activates signal transduction and leads to cellular processes that promote the uptake of ...
Pemvidutide also has been shown to increase the breakdown of fat and its mobilization within the liver, which may have beneficial effects on not only fat-related liver diseases like NASH, but also insulin resistance, a common problem in people with obesity. Pemvidutide incorporates the EuPortTM domain, a proprietary technology that increases its serum half-life ...
“This exciting clinical trial is the first to evaluate the ability of a procedural therapy to reduce or eliminate the need for insulin in patients with advanced type 2 diabetes, a critical therapeutic need. ...
The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to allow patients currently on insulin therapy but with inadequate glycemic control to achieve durable insulin-free glycemic control. ...
” Revita DMR (duodenal mucosal resurfacing) is a first-in-class intervention designed to reverse insulin resistance and metabolic disease progression. The outpatient procedure uses heat to resurface the lining of the upper intestine. ...
” The Revita DMR treatment harnesses breakthrough insights in intestinal biology and aims to reset key metabolic pathways, including insulin resistance, to reverse metabolic disease. This same-day, outpatient endoscopic procedure uses heat to resurface the lining of the upper intestine (duodenal mucosa) in a minimally invasive, outpatient procedure. ...
” Revita is a first-in-class intervention designed to target insulin resistance and metabolic disease progression by resetting key pathways in the gut that drive metabolic disease. ...
A number of treatments have been investigated in the past, including decreasing insulin resistance and modifying patient lifestyles. This paucity of solid treatments has led to a race between pharma and biotech companies to come up with the ultimate NASH therapy. ...
Vybion's programs in Huntington's disease, protein folding pathways and insulin resistant diabetes illustrate PharmCode ...
ByVybion